Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7183-7190

  Schimmer, Aaron D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 35156; ANTISENSE OLIGONUCLEOTIDE; CASPASE; CASPASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER DIAGNOSIS; CELL CYCLE; CELL DIVISION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; MITOCHONDRION; NONHUMAN; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CASPASES; ENZYME ACTIVATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; ISOENZYMES; PROTEINS;

EID: 5644259587     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1918     Document Type: Review

References (98)

1. Cryns V, Yuan Y. Proteases to die for. Genes Dev 1999;12:1551-70.
2. Thornberry NA, Lajebnik Y. Caspases: enemies within. Science (Wash DC) 1998; 281:1312-6.
3. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997; 91:443-6.
4. Zapata JM, Takahashi R, Salvesen GS, Reed JC. Granzyme release and caspase activation in activated human T-lymphocytes. J Biol Chem 1998;273:6916-20.
5. Barry M, Heibein JA, Pinkoski MJ, et al. Granzyme B short-circuits the need for caspase-8 activity during granule-mediated cytotoxic T-lymphocyte killing by directiy cleaving Bid. Mol Cell Biol 2000;20:3781-94.
6. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Wash DC) 1997;275:1132-6.
7. Saleh A, Srinivasula S, Acharya S, Fishel R, Ainemri E. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999;274:17941-5.
8. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405-13.
9. Chang H, Yang X, Baltimore D. Dissecting Fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation. Proc Natl Acad Sci USA 1999;96:1252-6.
10. Berglund H, Olerenshaw D, Sankar A, et al. The three-dimensional solution structure and dynamic properties of the human FADD death domain. J Mol Biol 2000;302:171-88.
11. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell 2003;11:529-41.
12. Kang J, Schaber M, Srinivasula S, et al. Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae. J Biol Chem 1999;274:3189-98.
13. Stennicke HR, Jürgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998;273:27084-90.
14. Tang D, Lahti JM, Kidd VJ, Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem 2000;275:9303-7.
15. Kulik G, Carson JP, Vomastek T, et al. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. Cancer Res 2001;61:2713-9.
16. L prevents this release but not TNF-R1/Fas death. J Biol Chem 1999;274:1156-63.
17. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993;67:2168-74.
18. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10.
19. Uren AG, Coulson EJ, Vaux DL. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. Trends Biochem Sci 1998;23:159-62.
20. Fraser A, James C, Evan G, Hengartner M. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr Biol 1999;9:292-301.
21. Li F, Flanary PL, Altieri DC, Dohlman HG. Cell division regulation by BIR1, a member of the inhibitor of apoptosis family in yeast. J Biol Chem 2000;275:6707-11.
22. Uren AG, Beilharz T, O'Connell MJ, et al. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division Proc Natl Acad Sci USA 1999;96:10170-5.
23. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. Available at: http://genomebiology. com/2001/2/7/reviews/3009.
24. Duckett C, Nava V, Gedrich R, et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996;15:2685-9.
25. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-23.
26. Deveraux QL, Leo E, Stennicke HR, et al. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999;18:5242-51.
27. Rothe M, Pan M-G, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995;83:1243-52.
28. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is perferentially expressed in human melanomas. Curr Biol 2000;10:1359-66.
29. Richter BWM, Mir SS, Eiben U, et al. Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol 2001;21:4292-301.
30. Roy N, Mahadevan MS, McLean M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995;80:167-78.
31. Maier JK, Lahoua Z, Gendron NH, et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J Neurosci 2002;22:2035-43.
32. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
33. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003;88:115-9.
34. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000;46:645-50.
35. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonie mucosa. Hum Pathol 2001;32:119-25.
36. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
37. Zhu ZB, Makhija SK, Lu B, et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 2004;11:256-62.
38. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell death proteases. Nature (Lond) 1997;388:300-4.
39. Sun C, Cal M, Gunasekera A, et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature (Lond) 1999;401:818-21.
40. Riedl SJ, Renatus M, Schwareenbacher R, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001;104:791-800.
41. Sun C, Cai M, Meadows RP, et al. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000;275:33777-81.
42. Shiozaki EN, Chai J, Rigotti DJ, et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003;11:519-27.
43. Bratton SB, Lewis J, Butterworth M, Duckett CS, Cohen GM. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95-and Bax-induced apoptosis. Cell Death Differ 2002;9:881-92.
44. Shin S, Sung B-J, Cho Y-S, et al. An anti-apoptotic protein human survivin ins a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40:1117-23.
45. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, and anticancer drugs. Cancer Res 1998;58:5315-20.
46. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood 2000;96:4002-3.
47. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003;22:2729-40.
48. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62:2462-7.
49. Temme A, Rieger M, Reber F, et al. Localization, dynamics, and function of survivin revealed by expression of functional survivin DsRed fusion proteins in the living cell. Mol Biol Cell 2003;14:78-92.
50. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (Lond) 1998;396:580-7.
51. Levkau B, Garton KJ, Ferri N, et al. xIAP induces cell-cycle arrest and activates nuclear factor-kappaB: new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res 2001;88:282-90.
52. Jordan BW, Dinev D, LeMellay V, et al. Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J Biol Chem 2001;276:39985-9.
53. Sanna MG, de Silva Correia J, Ducrey O, et al. IAP supression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 2002;22:1754-66.
54. Sanna MG, Duckett CS, Richter BW, Thompson CB, Ulevitch RJ. Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP. Proc Natl Acad Sci USA 1998;95:6015-20.
55. Hofer-Warbinek R, Schmid JA, Stehlik C, et al. Activation of NF-kB by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAKI. J Biol Chem 2000;275:22064-8.
56. Claveria C, Caminero E, Martinez AC, Campuzano S, Torres M. GH3, a novel proapoptotic domain in Drosophila Grim, promotes a mitochondrial death pathway. EMBO J 2002;21:3327-36.
57. Srinivasula SM, Datta P, Kobayashi M, et al. sickle, a novel Drosophila death gene in the reaper/hid/grim region, encodes an IAP-inhibitory protein. Curr Biol 2002;12:125-30.
58. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
59. Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
60. Verhagen AM, Silke J, Ekert PG, et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem 2002;277:445-54.
61. Suzuki Y, Imai Y, Nakayama H, et al. A serine protease, HtrA2/Omi, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001;8:613-21.
62. Amt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/ DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002;277:44236-43.
63. Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature (Lond) 2000;408:1004-8.
64. Yang L, Mashima T, Sato S, et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 2003;63:831-7.
65. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/ TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15.
66. Srinivasula SM, Hegde R, Saleh A, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature (Lond) 2001;410:112-6.
67. Li W, Srinivasula SM, Chai J, et al. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol 2002;9:436-41.
68. Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev 2003;17:1487-96.
69. Roberts DL, Merrison W, MacFarlane M, Cohen GM. The inhibitor of apoptosis protein-binding domain of Smac is not essential for its proapoptotic activity. J Cell Biol 2001;153:221-7.
70. Liston P, Fong WG, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 2001;3:128-33.
71. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
72. Lo Muzio L, Pannone G, Leonardi R, et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res 2003;82:923-8.
73. Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer (Phila) 2003;97:1077-83.
74. Miyachi K, Sasaki K, Onodera S, et al. Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 2003;6:217-24.
75. Schulte IJ, Kiemeney LA, Witjes JA, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003;23:3327-31.
76. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002;11:33-40.
77. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-25.
78. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
79. Carter BZ, Kornblau SM, Tsao T, et al. Caspase-independent cell death in AML: caspase-inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis. Blood 2003;102:4179-86.
80. Ferreira CG, van der Valk P, Span SW, et al. Expression of x-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 2001;7:2468-74.
81. Harlin H, Reffey SB, Duckett CS, Lindsten T, Thompson CB. Characterization of XIAP-deficient mice. Mol Cell Biol 2001;21:3604-8.
82. Holcik M, Thompson CS, Yaraghi Z, et al. The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc Natl Acad Sci USA 2000;97:2286-90.
83. Hay BA, Wassarman DA, Rubin GM. Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. Cell 1995;83:1253-62.
84. Crooke ST. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev 1998;8:133-4.
85. Olie RA, Simões-Wüst AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000;60:2805-9.
86. Xia C, Xu Z, Yuan X, et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002;1:687-94.
87. Tu SP, Jiang XH, Lin MC, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003;63:7724-32.
88. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst (Bethesda) 2001;93:1541-52.
89. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Investig 2001;108:981-90.
90. Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000;19:4174-7.
91. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000;60:5659-66.
92. Bilim V, Kasahara T, Hara N, Takahashi K, Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistance TCC in vitro. Int J Cancer 2003; 103:29-37.
93. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003;9:2826-36.
94. Glover CJ, Kite K, DeLosh R, et al. A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal Biochem 2003;320:157-69.
95. Kipp RA, Case MA, Wist AD, et al. Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners. Biochemistry 2002;41:7344-9.
96. Tamm I, Trepel M, Welsh K, et al. Peptides targeting caspase inhibitors. J Biol Chem 2003;278:14401-5.
97. Wu TY, Wagner KW, Bursulaya B, Schultz PG, Deveraux QL. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol 2003;10:759-67.
98. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004;5:25-35.